A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07174908 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: IN10018 in combination with D-1553
DRUG: anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed

Sponsor

InxMed (Shanghai) Co., Ltd.